Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




AI Tool Identifies Novel Genetic Signatures to Personalize Cancer Therapies

By LabMedica International staff writers
Posted on 15 Nov 2024

Lung cancer and bladder cancer are among the most commonly diagnosed cancers globally. More...

Researchers have now developed artificial intelligence (AI) models designed to personalize immune therapies for oncology patients.

In a new study, scientists at the Institute of Science of Data and Artificial Intelligence (DATAI) at the University of Navarra (Pamplona, Spain) analyzed data from over 3,000 patients diagnosed with lung and bladder cancers. By employing machine learning models, the researchers discovered new genetic signatures unique to each stage of these cancers and created a system known as the "IFIT index" (Index of "Physical Immunity"). This system is aimed at personalizing therapies to enhance their effectiveness. The IFIT index measures a patient's immunological fitness, categorizing them based on their risk at various stages of the disease. This approach allows for predicting how well a patient will respond to treatment depending on the activity of their immune system in different stages of cancer treatment.

The research, published in the Journal for ImmunoTherapy of Cancer, is based on an analysis of the cancer immunity cycle (CIC), which looks at how immune system signals affect the success of immunotherapy. Using this framework and AI tools, the researchers identified specific patterns of cellular activity linked to the molecular stages of the disease and developed the IFIT index. This innovation highlights the potential of AI in advancing personalized medicine and offers new prospects in the fight against cancer. The team also indicated that this technique will continue to be refined through future collaborative studies involving other cancer types.

"Immunotherapy represents one of the most promising frontiers in the fight against cancer, and by using artificial intelligence models, we can further fine-tune treatments based on each patient's immune profile," said Rubén Armañanzas, leader of DATAI's laboratory Digital Medicine and one of the lead authors of the study.

 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.